CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Revenue:
Total revenue	$ 2,556	$ 4,866	$ 5,682	$ 17,964
Operating expenses:
Cost of goods sold		1,558	620	5,566
Research and development	1,362	25,451	32,634	80,095
General and administrative	6,475	6,755	19,699	21,191
Restructuring	707		5,689
Total operating expenses	8,544	33,764	58,642	106,852
Operating loss	(5,988)	(28,898)	(52,960)	(88,888)
Other income, net	766	866	2,407	2,712
Impairment of long-lived assets	(4,274)		(4,274)
Inventory write-down	(1,020)		(2,509)
Non-cash interest expense on liability related to sales of future royalties and milestones	(1,960)		(5,852)
Net loss	$ (12,476)	$ (28,032)	$ (63,188)	$ (86,176)
Net loss per share:
Basic (in dollars per share)	$ (0.23)	$ (0.52)	$ (1.15)	$ (1.59)
Diluted (in dollars per share)	$ (0.23)	$ (0.52)	$ (1.15)	$ (1.59)
Weighted average shares:
Basic (in shares)	54,843,841	54,235,695	54,719,330	54,038,239
Diluted (in shares)	54,843,841	54,235,695	54,719,330	54,038,239
Other comprehensive income, net of tax of $0:
Change in unrealized gains on available-for-sale marketable securities	$ 96	$ 291	$ 235	$ 1,233
Total comprehensive loss	(12,380)	(27,741)	(62,953)	(84,943)
Collaborative revenue
Revenue:
Total revenue	1,298	2,471	2,086	10,631
Commercial supply revenue
Revenue:
Total revenue		1,252	640	5,843
License and milestone fees
Revenue:
Total revenue		910		910
Royalty revenue
Revenue:
Total revenue		167		415
Clinical compound revenue
Revenue:
Total revenue		$ 66	84	$ 165
Other revenue
Revenue:
Total revenue	$ 1,258		$ 2,872